« Back to the previous page
CDMO in Central Europe for Sale
Company for sale
- Revenue: > 15 € M
- Established: several decades ago
- Stake for sale: Controlling stake
- Location of this pharma manufacturer: Central Europe
- Valuation: >20m Euro
- #CFIE PHS059
Overview of this CDMO in Central Europe for Sale
This CDMO has established manufacturing contracts with a host of pharmaceutical companies across the globe for the Central and Eastern Europe markets, like Germany and Switzerland.
Representative clients include the major generics companies with a diversified client base of 50+ pharma companies.
Production capacity is divided into two plants, with capsule, tablet, blister & sachet lines. Current soft capsule capacity of up to 1 billion million units/year will be enlarged with a new line set to come on stream.
Innovative CDMO with a track record of almost 20 years in the manufacturing of food supplements, syrups, cosmetics as well as of medical and food preparation products. Other revenue sources include regulatory pharmaceutical and marketing services and the distribution of medical devices. Upward trending EBITDA of 20% the last years.
Profile (strategy) of this CDMO in Central Europe for Sale
From the start around two decades ago, the company has developed a high-quality culture and evolved into a more international firm, with trade partnerships spanning from the USA to China, Japan or the EU. A more recent focus on product innovation has resulted in the launching of two pioneering products in the home market, for probiotic drops and sticks.
Further international expansion into the Americas and Asia is envisaged.
Activities and products of this CDMO in Central Europe for Sale
This Central European CDMO is focused on manufacturing high-quality food supplements, cosmetics and syrup formulations as well as on medical & food preparations.
Highlights of this CDMO in Central Europe for Sale
- Established, loyal client base among a host of international and regional pharmaceutical companies
- Growing local and export sales
- Rising EBITDA margin (20%+)
- Capsule line expansion with state-of-the-art technology
- Strong quality culture
- Product innovation skills
- Long-standing knowledge transfer from multiple international clients from the EU, Asia or America
Information about this CDMO in Central Europe for Sale